Literature DB >> 24290900

Clinical characteristics and prediction of pulmonary hypertension in severe emphysema.

Omar A Minai1, Henry Fessler2, James K Stoller3, Gerard J Criner4, Steven M Scharf5, Yvonne Meli6, Benjamin Nutter7, Malcolm M DeCamp8.   

Abstract

BACKGROUND: We explored the prevalence, clinical and physiologic correlates of pulmonary hypertension (PH), and screening strategies in patients with severe emphysema evaluated for the National Emphysema Treatment Trial (NETT).
METHODS: Patients undergoing Doppler echocardiography (DE) and right heart catheterization were included. Patients with mean pulmonary arterial pressure ≥ 25 mmHg (PH Group) were compared to the remainder (non-PH Group).
RESULTS: Of 797 patients, 302 (38%) had PH and 18 (2.2%) had severe PH. Compared to the non-PH Group, patients with PH had lower % predicted FEV1 (p < 0.001), % predicted diffusion capacity for carbon monoxide (p = 0.006), and resting room air PaO2 (p < 0.001). By multivariate analysis, elevated right ventricular systolic pressure, reduced resting room air PaO2, reduced post-bronchodilator % predicted FEV1, and enlarged pulmonary arteries on computed tomographic scan were the best predictors of PH. A strategy using % predicted FEV1, % predicted DLCO, PaO2, and RVSP was predictive of the presence of pre-capillary PH and was highly predictive of its absence.
CONCLUSIONS: Mildly elevated pulmonary artery pressures are found in a significant proportion of patients with severe emphysema. However, severe PH is uncommon in the absence of co-morbidities. Simple non-invasive tests may be helpful in screening patients for pre-capillary PH in severe emphysema but none is reliably predictive of its presence.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Emphysema; Hypoxemia; Lung disease; Pulmonary hypertension

Mesh:

Substances:

Year:  2013        PMID: 24290900     DOI: 10.1016/j.rmed.2013.11.006

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

1.  Diffusing Capacity Is an Independent Predictor of Outcomes in Pulmonary Hypertension Associated With COPD.

Authors:  Aparna Balasubramanian; Todd M Kolb; Rachel L Damico; Paul M Hassoun; Meredith C McCormack; Stephen C Mathai
Journal:  Chest       Date:  2020-03-14       Impact factor: 9.410

2.  Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method.

Authors:  Carolina S G Freitas; Bruno G Baldi; Carlos Jardim; Mariana S Araujo; Juliana Barbosa Sobral; Gláucia I Heiden; Ronaldo A Kairalla; Rogério Souza; Carlos R R Carvalho
Journal:  Orphanet J Rare Dis       Date:  2017-04-20       Impact factor: 4.123

3.  Query-constraint-based mining of association rules for exploratory analysis of clinical datasets in the National Sleep Research Resource.

Authors:  Rashmie Abeysinghe; Licong Cui
Journal:  BMC Med Inform Decis Mak       Date:  2018-07-23       Impact factor: 2.796

4.  Predictive value of pulmonary function testing in the evaluation of pulmonary hypertension in sarcoidosis.

Authors:  Arun Jose; Joseph Delio; Jonathan Gwizdala; Hannah Goulart; Jalil E Ahari
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-03-09       Impact factor: 0.670

Review 5.  Pulmonary hypertension and right heart dysfunction in chronic lung disease.

Authors:  Amirmasoud Zangiabadi; Carmine G De Pasquale; Dimitar Sajkov
Journal:  Biomed Res Int       Date:  2014-07-24       Impact factor: 3.411

6.  Accuracy of CT Pulmonary Artery Diameter for Pulmonary Hypertension in End-Stage COPD.

Authors:  Firdaus A Mohamed Hoesein; Tim Besselink; Esther Pompe; Erik-Jan Oudijk; Ed A de Graaf; J M Kwakkel-van Erp; Pim A de Jong; Bart Luijk
Journal:  Lung       Date:  2016-07-16       Impact factor: 2.584

7.  Characteristics of Chronic Obstructive Pulmonary Disease Patients with Pulmonary Hypertension Assessed by Echocardiography in a Three-Year Observational Cohort Study.

Authors:  Shingo Nakayama; Shotaro Chubachi; Kaori Sakurai; Hidehiro Irie; Akihiro Tsutsumi; Mizuha Hashiguchi; Yuji Itabashi; Mitsushige Murata; Hidetoshi Nakamura; Koichiro Asano; Koichi Fukunaga
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-03-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.